All In Biotech

Drug Trial Radar · NCT06246916

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

560

Planned (sponsor's estimate)

Start

Sep 9, 2024

Primary completion

Mar 22, 2027

Study completion Jul 10, 2033

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Feb 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™ and approved for the treatment of melanoma in adults and children. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs. * How much study drug is in the blood at different times. * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)

Conditions

  • Melanoma

Interventions

  • fianlimabDrug

    Intravenous (IV) administration every 3 weeks (Q3W) in combination with cemiplimab

  • cemiplimabDrug

    IV administration Q3W in combination with fianlimab

  • relatlimab+nivolumabDrug

    IV administration every 4 weeks (Q4W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on blinded independent central review (BICR)Time frame: Up to 72 months

Locations

113 sites in 2 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Centers

    Chandler, Arizona · Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Arizona Oncology Associates

    Tucson, Arizona · Withdrawn

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Withdrawn

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Recruiting

  • University of California Los Angeles

    Los Angeles, California · Recruiting

  • St. Joseph Hospital Orange

    Orange, California · Recruiting

  • University of California Irvine, UCI Medical Center

    Orange, California · Recruiting

  • Eisenhower Medical Center

    Rancho Mirage, California · Withdrawn

  • Emad Ibrahim, MD, Inc.

    Redlands, California · Recruiting

  • Sutter Health

    Sacramento, California · Recruiting

  • University of California San Francisco (UCSF)

    San Francisco, California · Recruiting

  • Sansum Clinic

    Santa Barbara, California · Withdrawn

  • St John's Cancer Institute

    Santa Monica, California · Withdrawn

  • Rocky Mountain Regional VA Medical Center

    Aurora, Colorado · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • The Melanoma And Skin Cancer Institute

    Englewood, Colorado · Recruiting

  • UCHealth

    Fort Collins, Colorado · Withdrawn

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Clermont Oncology Center

    Clermont, Florida · Withdrawn

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Cancer Specialist of North Florida

    Jacksonville, Florida · Withdrawn

  • Boca Raton Clinical Research (BRCR) Global

    Tamarac, Florida · Recruiting

  • H. Lee Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University Cancer & Blood Center

    Athens, Georgia · Recruiting

  • John B. Amos Cancer Center

    Columbus, Georgia · Withdrawn

  • Beacon Clinic

    Coeur d'Alene, Idaho · Recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Recruiting

  • Advocate Lutheran General Hospital

    Park Ridge, Illinois · Recruiting

  • Illinois CancerCare

    Peoria, Illinois · Recruiting

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana · Recruiting

  • The University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • Markey Cancer Center Clinical Research Organization

    Lexington, Kentucky · Completed

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Withdrawn

  • Maryland Oncology Hematology, P.A.

    Columbia, Maryland · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Withdrawn

  • Henry Ford Cancer Institute/Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Minnesota Oncology Hematology, P.A

    Fridley, Minnesota · Recruiting

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.